nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—Ifosfamide—testicular cancer	0.685	1	CrCtD
Cyclophosphamide—CYP2C18—Ifosfamide—testicular cancer	0.0439	0.211	CbGbCtD
Cyclophosphamide—CYP2A6—Ifosfamide—testicular cancer	0.0213	0.103	CbGbCtD
Cyclophosphamide—CYP3A7—Ifosfamide—testicular cancer	0.0146	0.0701	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0146	0.0701	CbGbCtD
Cyclophosphamide—CYP2B6—Ifosfamide—testicular cancer	0.0139	0.0668	CbGbCtD
Cyclophosphamide—CYP3A5—Ifosfamide—testicular cancer	0.0109	0.0526	CbGbCtD
Cyclophosphamide—CYP2C8—Ifosfamide—testicular cancer	0.0105	0.0506	CbGbCtD
Cyclophosphamide—CYP2C19—Ifosfamide—testicular cancer	0.00882	0.0424	CbGbCtD
Cyclophosphamide—CYP2C9—Ifosfamide—testicular cancer	0.00733	0.0353	CbGbCtD
Cyclophosphamide—CYP2B6—Cisplatin—testicular cancer	0.00675	0.0325	CbGbCtD
Cyclophosphamide—ABCB1—Dactinomycin—testicular cancer	0.00603	0.029	CbGbCtD
Cyclophosphamide—CYP3A5—Etoposide—testicular cancer	0.00523	0.0251	CbGbCtD
Cyclophosphamide—CYP2C8—Etoposide—testicular cancer	0.00502	0.0242	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—testicular cancer	0.00452	0.0218	CbGbCtD
Cyclophosphamide—CYP3A4—Ifosfamide—testicular cancer	0.00426	0.0205	CbGbCtD
Cyclophosphamide—ABCB1—Vinblastine—testicular cancer	0.00378	0.0182	CbGbCtD
Cyclophosphamide—CYP2C9—Cisplatin—testicular cancer	0.00357	0.0172	CbGbCtD
Cyclophosphamide—CYP2D6—Vinblastine—testicular cancer	0.00356	0.0171	CbGbCtD
Cyclophosphamide—ABCB1—Cisplatin—testicular cancer	0.00346	0.0167	CbGbCtD
Cyclophosphamide—ABCB1—Etoposide—testicular cancer	0.0034	0.0164	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—testicular cancer	0.00232	0.0112	CbGbCtD
Cyclophosphamide—CYP3A4—Vinblastine—testicular cancer	0.00226	0.0109	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—testicular cancer	0.00225	0.0108	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—testicular cancer	0.00219	0.0105	CbGbCtD
Cyclophosphamide—CYP3A4—Etoposide—testicular cancer	0.00204	0.0098	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—testicular cancer	0.00139	0.00669	CbGbCtD
Cyclophosphamide—Decreased appetite—Cisplatin—testicular cancer	2.26e-05	0.000211	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dactinomycin—testicular cancer	2.25e-05	0.00021	CcSEcCtD
Cyclophosphamide—Pneumonia—Methotrexate—testicular cancer	2.25e-05	0.00021	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—testicular cancer	2.25e-05	0.00021	CcSEcCtD
Cyclophosphamide—Vomiting—Bleomycin—testicular cancer	2.24e-05	0.00021	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—testicular cancer	2.23e-05	0.000208	CcSEcCtD
Cyclophosphamide—Hypotension—Etoposide—testicular cancer	2.23e-05	0.000208	CcSEcCtD
Cyclophosphamide—Rash—Bleomycin—testicular cancer	2.23e-05	0.000208	CcSEcCtD
Cyclophosphamide—Pain—Cisplatin—testicular cancer	2.22e-05	0.000208	CcSEcCtD
Cyclophosphamide—Dermatitis—Bleomycin—testicular cancer	2.22e-05	0.000208	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Ifosfamide—testicular cancer	2.22e-05	0.000208	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—testicular cancer	2.22e-05	0.000207	CcSEcCtD
Cyclophosphamide—Renal failure—Methotrexate—testicular cancer	2.2e-05	0.000205	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—testicular cancer	2.18e-05	0.000204	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—testicular cancer	2.18e-05	0.000203	CcSEcCtD
Cyclophosphamide—Asthenia—Ifosfamide—testicular cancer	2.16e-05	0.000202	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—testicular cancer	2.15e-05	0.0002	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Cisplatin—testicular cancer	2.14e-05	0.0002	CcSEcCtD
Cyclophosphamide—Paraesthesia—Etoposide—testicular cancer	2.14e-05	0.0002	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—testicular cancer	2.14e-05	0.0002	CcSEcCtD
Cyclophosphamide—Pruritus—Ifosfamide—testicular cancer	2.13e-05	0.000199	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—testicular cancer	2.13e-05	0.000199	CcSEcCtD
Cyclophosphamide—Dyspnoea—Etoposide—testicular cancer	2.12e-05	0.000198	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—testicular cancer	2.12e-05	0.000198	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—testicular cancer	2.11e-05	0.000197	CcSEcCtD
Cyclophosphamide—Nausea—Bleomycin—testicular cancer	2.1e-05	0.000196	CcSEcCtD
Cyclophosphamide—Vomiting—Dactinomycin—testicular cancer	2.09e-05	0.000195	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—testicular cancer	2.09e-05	0.000195	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—testicular cancer	2.08e-05	0.000194	CcSEcCtD
Cyclophosphamide—Rash—Dactinomycin—testicular cancer	2.08e-05	0.000194	CcSEcCtD
Cyclophosphamide—Decreased appetite—Etoposide—testicular cancer	2.07e-05	0.000193	CcSEcCtD
Cyclophosphamide—Diarrhoea—Ifosfamide—testicular cancer	2.06e-05	0.000193	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—testicular cancer	2.06e-05	0.000193	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—testicular cancer	2.06e-05	0.000192	CcSEcCtD
Cyclophosphamide—Body temperature increased—Cisplatin—testicular cancer	2.06e-05	0.000192	CcSEcCtD
Cyclophosphamide—Fatigue—Etoposide—testicular cancer	2.05e-05	0.000192	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—testicular cancer	2.05e-05	0.000192	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—testicular cancer	2.04e-05	0.000191	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—testicular cancer	2.04e-05	0.000191	CcSEcCtD
Cyclophosphamide—Constipation—Etoposide—testicular cancer	2.04e-05	0.00019	CcSEcCtD
Cyclophosphamide—Pain—Etoposide—testicular cancer	2.04e-05	0.00019	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—testicular cancer	2.04e-05	0.00019	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—testicular cancer	2.02e-05	0.000189	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—testicular cancer	2.01e-05	0.000188	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—testicular cancer	2.01e-05	0.000188	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—testicular cancer	2.01e-05	0.000187	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—testicular cancer	2e-05	0.000186	CcSEcCtD
Cyclophosphamide—Dizziness—Ifosfamide—testicular cancer	2e-05	0.000186	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—testicular cancer	1.98e-05	0.000185	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Etoposide—testicular cancer	1.96e-05	0.000183	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—testicular cancer	1.96e-05	0.000183	CcSEcCtD
Cyclophosphamide—Nausea—Dactinomycin—testicular cancer	1.96e-05	0.000183	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—testicular cancer	1.95e-05	0.000182	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—testicular cancer	1.95e-05	0.000182	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—testicular cancer	1.94e-05	0.000181	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	1.92e-05	0.000179	CcSEcCtD
Cyclophosphamide—Vomiting—Ifosfamide—testicular cancer	1.92e-05	0.000179	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Cisplatin—testicular cancer	1.92e-05	0.000179	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—testicular cancer	1.91e-05	0.000179	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—testicular cancer	1.9e-05	0.000178	CcSEcCtD
Cyclophosphamide—Rash—Ifosfamide—testicular cancer	1.9e-05	0.000178	CcSEcCtD
Cyclophosphamide—Dermatitis—Ifosfamide—testicular cancer	1.9e-05	0.000177	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—testicular cancer	1.9e-05	0.000177	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—testicular cancer	1.9e-05	0.000177	CcSEcCtD
Cyclophosphamide—Urticaria—Etoposide—testicular cancer	1.89e-05	0.000177	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—testicular cancer	1.89e-05	0.000176	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—testicular cancer	1.89e-05	0.000176	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—testicular cancer	1.89e-05	0.000176	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—testicular cancer	1.88e-05	0.000176	CcSEcCtD
Cyclophosphamide—Body temperature increased—Etoposide—testicular cancer	1.88e-05	0.000176	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—testicular cancer	1.88e-05	0.000176	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—testicular cancer	1.88e-05	0.000176	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—testicular cancer	1.88e-05	0.000176	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—testicular cancer	1.87e-05	0.000175	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—testicular cancer	1.87e-05	0.000175	CcSEcCtD
Cyclophosphamide—Asthenia—Cisplatin—testicular cancer	1.87e-05	0.000174	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—testicular cancer	1.86e-05	0.000173	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—testicular cancer	1.85e-05	0.000173	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—testicular cancer	1.81e-05	0.000169	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—testicular cancer	1.81e-05	0.000169	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—testicular cancer	1.8e-05	0.000168	CcSEcCtD
Cyclophosphamide—Nausea—Ifosfamide—testicular cancer	1.79e-05	0.000167	CcSEcCtD
Cyclophosphamide—Diarrhoea—Cisplatin—testicular cancer	1.78e-05	0.000166	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—testicular cancer	1.78e-05	0.000166	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—testicular cancer	1.78e-05	0.000166	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—testicular cancer	1.77e-05	0.000165	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Etoposide—testicular cancer	1.76e-05	0.000164	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—testicular cancer	1.75e-05	0.000164	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—testicular cancer	1.75e-05	0.000163	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—testicular cancer	1.75e-05	0.000163	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—testicular cancer	1.74e-05	0.000163	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—testicular cancer	1.74e-05	0.000163	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—testicular cancer	1.74e-05	0.000162	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—testicular cancer	1.74e-05	0.000162	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—testicular cancer	1.73e-05	0.000162	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—testicular cancer	1.71e-05	0.00016	CcSEcCtD
Cyclophosphamide—Asthenia—Etoposide—testicular cancer	1.71e-05	0.00016	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—testicular cancer	1.69e-05	0.000158	CcSEcCtD
Cyclophosphamide—Pruritus—Etoposide—testicular cancer	1.69e-05	0.000157	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—testicular cancer	1.68e-05	0.000157	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—testicular cancer	1.68e-05	0.000157	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—testicular cancer	1.66e-05	0.000155	CcSEcCtD
Cyclophosphamide—Vomiting—Cisplatin—testicular cancer	1.65e-05	0.000154	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—testicular cancer	1.65e-05	0.000154	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—testicular cancer	1.64e-05	0.000154	CcSEcCtD
Cyclophosphamide—Rash—Cisplatin—testicular cancer	1.64e-05	0.000153	CcSEcCtD
Cyclophosphamide—Dermatitis—Cisplatin—testicular cancer	1.64e-05	0.000153	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—testicular cancer	1.64e-05	0.000153	CcSEcCtD
Cyclophosphamide—Diarrhoea—Etoposide—testicular cancer	1.63e-05	0.000152	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—testicular cancer	1.62e-05	0.000152	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—testicular cancer	1.62e-05	0.000151	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—testicular cancer	1.62e-05	0.000151	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—testicular cancer	1.61e-05	0.000151	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—testicular cancer	1.6e-05	0.00015	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—testicular cancer	1.58e-05	0.000147	CcSEcCtD
Cyclophosphamide—Dizziness—Etoposide—testicular cancer	1.58e-05	0.000147	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—testicular cancer	1.57e-05	0.000147	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—testicular cancer	1.57e-05	0.000146	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—testicular cancer	1.56e-05	0.000146	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—testicular cancer	1.55e-05	0.000145	CcSEcCtD
Cyclophosphamide—Nausea—Cisplatin—testicular cancer	1.54e-05	0.000144	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—testicular cancer	1.54e-05	0.000144	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—testicular cancer	1.54e-05	0.000144	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—testicular cancer	1.53e-05	0.000142	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—testicular cancer	1.52e-05	0.000142	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—testicular cancer	1.52e-05	0.000141	CcSEcCtD
Cyclophosphamide—Vomiting—Etoposide—testicular cancer	1.52e-05	0.000141	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—testicular cancer	1.51e-05	0.000141	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—testicular cancer	1.51e-05	0.000141	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—testicular cancer	1.5e-05	0.00014	CcSEcCtD
Cyclophosphamide—Rash—Etoposide—testicular cancer	1.5e-05	0.00014	CcSEcCtD
Cyclophosphamide—Dermatitis—Etoposide—testicular cancer	1.5e-05	0.00014	CcSEcCtD
Cyclophosphamide—Headache—Etoposide—testicular cancer	1.49e-05	0.000139	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—testicular cancer	1.49e-05	0.000139	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—testicular cancer	1.49e-05	0.000139	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—testicular cancer	1.49e-05	0.000139	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—testicular cancer	1.48e-05	0.000138	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—testicular cancer	1.48e-05	0.000138	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—testicular cancer	1.47e-05	0.000137	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—testicular cancer	1.46e-05	0.000137	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—testicular cancer	1.46e-05	0.000136	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—testicular cancer	1.45e-05	0.000135	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—testicular cancer	1.44e-05	0.000134	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—testicular cancer	1.43e-05	0.000133	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—testicular cancer	1.43e-05	0.000133	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—testicular cancer	1.43e-05	0.000133	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—testicular cancer	1.42e-05	0.000132	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—testicular cancer	1.42e-05	0.000132	CcSEcCtD
Cyclophosphamide—Nausea—Etoposide—testicular cancer	1.42e-05	0.000132	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—testicular cancer	1.41e-05	0.000132	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—testicular cancer	1.41e-05	0.000131	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—testicular cancer	1.4e-05	0.000131	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—testicular cancer	1.4e-05	0.00013	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—testicular cancer	1.39e-05	0.00013	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—testicular cancer	1.39e-05	0.00013	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—testicular cancer	1.39e-05	0.00013	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—testicular cancer	1.39e-05	0.00013	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methotrexate—testicular cancer	1.38e-05	0.000129	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—testicular cancer	1.38e-05	0.000129	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—testicular cancer	1.37e-05	0.000128	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—testicular cancer	1.36e-05	0.000127	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—testicular cancer	1.36e-05	0.000127	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—testicular cancer	1.35e-05	0.000126	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—testicular cancer	1.34e-05	0.000125	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—testicular cancer	1.34e-05	0.000125	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—testicular cancer	1.34e-05	0.000125	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—testicular cancer	1.33e-05	0.000125	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—testicular cancer	1.33e-05	0.000124	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—testicular cancer	1.32e-05	0.000123	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—testicular cancer	1.31e-05	0.000123	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—testicular cancer	1.31e-05	0.000123	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—testicular cancer	1.31e-05	0.000122	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—testicular cancer	1.31e-05	0.000122	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—testicular cancer	1.3e-05	0.000122	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—testicular cancer	1.3e-05	0.000121	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—testicular cancer	1.29e-05	0.000121	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—testicular cancer	1.29e-05	0.00012	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—testicular cancer	1.29e-05	0.00012	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—testicular cancer	1.29e-05	0.00012	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—testicular cancer	1.28e-05	0.00012	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—testicular cancer	1.27e-05	0.000119	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—testicular cancer	1.27e-05	0.000119	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—testicular cancer	1.27e-05	0.000119	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—testicular cancer	1.25e-05	0.000117	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—testicular cancer	1.25e-05	0.000116	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—testicular cancer	1.24e-05	0.000116	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—testicular cancer	1.24e-05	0.000115	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—testicular cancer	1.24e-05	0.000115	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—testicular cancer	1.23e-05	0.000115	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—testicular cancer	1.23e-05	0.000115	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—testicular cancer	1.22e-05	0.000114	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—testicular cancer	1.22e-05	0.000114	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—testicular cancer	1.22e-05	0.000114	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—testicular cancer	1.21e-05	0.000113	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—testicular cancer	1.21e-05	0.000113	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—testicular cancer	1.2e-05	0.000112	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—testicular cancer	1.19e-05	0.000112	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—testicular cancer	1.19e-05	0.000111	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—testicular cancer	1.18e-05	0.00011	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—testicular cancer	1.18e-05	0.00011	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—testicular cancer	1.16e-05	0.000108	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—testicular cancer	1.15e-05	0.000108	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—testicular cancer	1.15e-05	0.000108	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—testicular cancer	1.14e-05	0.000107	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—testicular cancer	1.14e-05	0.000107	CcSEcCtD
Cyclophosphamide—Urticaria—Methotrexate—testicular cancer	1.13e-05	0.000106	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—testicular cancer	1.13e-05	0.000105	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	1.13e-05	0.000105	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—testicular cancer	1.11e-05	0.000104	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—testicular cancer	1.1e-05	0.000103	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—testicular cancer	1.1e-05	0.000103	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—testicular cancer	1.07e-05	0.0001	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—testicular cancer	1.07e-05	9.95e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—testicular cancer	1.06e-05	9.91e-05	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—testicular cancer	1.06e-05	9.87e-05	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—testicular cancer	1.06e-05	9.87e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—testicular cancer	1.06e-05	9.86e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—testicular cancer	1.05e-05	9.82e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—testicular cancer	1.02e-05	9.56e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—testicular cancer	1.02e-05	9.51e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—testicular cancer	1.01e-05	9.43e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—testicular cancer	9.84e-06	9.19e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—testicular cancer	9.82e-06	9.17e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—testicular cancer	9.77e-06	9.12e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—testicular cancer	9.77e-06	9.12e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—testicular cancer	9.58e-06	8.95e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—testicular cancer	9.45e-06	8.82e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—testicular cancer	9.44e-06	8.81e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—testicular cancer	9.14e-06	8.53e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—testicular cancer	9.11e-06	8.5e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Methotrexate—testicular cancer	9.07e-06	8.47e-05	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—testicular cancer	9e-06	8.4e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—testicular cancer	8.99e-06	8.4e-05	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—testicular cancer	8.94e-06	8.35e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—testicular cancer	8.87e-06	8.28e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—testicular cancer	8.83e-06	8.25e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—testicular cancer	8.74e-06	8.16e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—testicular cancer	8.49e-06	7.93e-05	CcSEcCtD
Cyclophosphamide—Nausea—Methotrexate—testicular cancer	8.48e-06	7.92e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—testicular cancer	8.46e-06	7.9e-05	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—testicular cancer	8.42e-06	7.86e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—testicular cancer	8.41e-06	7.86e-05	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—testicular cancer	8.37e-06	7.81e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—testicular cancer	8.17e-06	7.63e-05	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—testicular cancer	7.93e-06	7.41e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—testicular cancer	7.86e-06	7.34e-05	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—testicular cancer	7.79e-06	7.28e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—testicular cancer	7.79e-06	7.27e-05	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—testicular cancer	7.74e-06	7.23e-05	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—testicular cancer	7.34e-06	6.85e-05	CcSEcCtD
